Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome

Autoimmunity Reviews

Volumn 6, Issue 2, 2006, Pages 98-103

  Erkan, Doruk ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Anticardiolipin antibody; Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Lupus anticoagulant test; Multiple organ dysfunction syndrome

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DNA VACCINE; DROTRECOGIN; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; HIRUDIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; THROMBIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VITAMIN K GROUP;

ANTIBIOTIC PROPHYLAXIS; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; CLINICAL FEATURE; CORTICOSTEROID THERAPY; EVIDENCE BASED MEDICINE; HUMAN; INTENSIVE CARE UNIT; PLASMAPHERESIS; PROGNOSIS; REVIEW; SEPSIS; TERMINAL DISEASE; THROMBOCYTOPENIA;

ANIMALS; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; CATASTROPHIC ILLNESS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PLASMA EXCHANGE; PLASMAPHERESIS; PROGNOSIS; PROTEIN C;

EID: 33751429820     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.06.013     Document Type: Review

References (40)

1. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4 (2006) 295-306
2. Erkan D., Cervera R., and Asherson R.A. Catastrophic antiphospholipid syndrome: where do we stand?. Arthritis Rheum 48 (2003) 3320-3327
3. Vero S., Asherson R.A., and Erkan D. Critical Care Review: Catastrophic Antiphospholipid Syndrome. J Intensive Care Med 21 (2006) 144-159
4. Asherson R.A., Cervera R., de Groot P.G., et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12 (2003) 530-534
5. Bucciarelli S, Espinosa G, Cervera R, et al. Mortality in the Catastrophic Antiphospholipid Syndrome: Prognostic Factors in a Series of 250 Patients. Arthritis and Rheum. In press.
6. Franklin R.D., and Kutteh W.H. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol 101 (2003) 455-462
7. Girardi G., Redecha P., and Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10 (2004) 1222-1226
8. Christman J.W., Lancaster L.H., and Blackwell T.S. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 24 (1998) 1131-1138
9. Dunoyer-Geindre S., de Moerloose P., Galve-de Rochemonteix B., et al. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost 88 (2002) 851-857
10. Scheinman, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270 (1995) 283-286
11. Annane D. Glucocorticoids in the treatment of severe sepsis and septic shock. Curr Opin Crit Care 11 (2005) 449-453
12. Orbach H., Katz U., Sherer Y., and Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 29 (2005) 173-184
13. Anonymous. FDA interim statement regarding immune globulin intravenous (IVIG). 8-27 - (GENERIC) Ref Type: Report. Washington, DC: FDA, 2002.
14. Uthman I., Shamseddine A., and Taher A. The role of therapeutic plasma exchange in catastrophic antiphospholipid syndrome. Transfus Apher Sci 33 (2005) 11-17
15. Tenedious R., Erkan D., and Lockshin M.D. Rituximab in the primary antiphospholipid syndrome. Arthritis Rheum 52 (2005) 4078 [abstract]
16. Erdozain J.G., Ruiz-Irastorza G., Egurbide M.V., et al. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica 89 (2004) ECR34 [abstract]
17. Rubenstein E., Arkfeld D.G., Metyas S., Shinada S., Ehresmann S., and Liebman H.A. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 33 (2006) 355-357
18. Yamazaki, et al. Rituximab decreases antiphospholipid antibody titers and improves hypercoagulable state without recurrent thrombosis: 2 year follow-up. Thromb Res 114 (2004) 610 [abstract]
19. Tommasino, et al. Short-term lack of efficacy of rituximab in a thrombocytopaenic patient with primary antiphospholipid syndrome. Thromb Res 114 (2004) 652 [abstract]
20. Blank M., Krause I., Wildbaum G., Karin N., and Shoenfeld Y. TNF alpha DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome. Lupus 12 (2003) 546-549
21. Berman J., Girardi G., and Salmon J.E. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 174 (2005) 485-490
22. Jonsdottir T., Forslid J., van Vollenhoven A., et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 63 (2004) 1075-1078
23. Eichacker P.Q., Parent C., Kalil A., et al. Risk and efficacy of anti-inflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 166 (2002) 1197-1205
24. Tracey K.J., Fong Y., Hesse D.G., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330 (1987) 662-664
25. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101 (1992) 1644-1655
26. Buras J.A., Holzmann B., and Sithovsky Ml. Animal models of sepsis: setting the stage. Nat Rev Drug Discov 4 (2005) 854-865
27. Lopez-Aguirre Y., and Paramo J.A. Endothelial cell and hemostatic activation in relation to cytokines in patients with sepsis. Thromb Res 94 (1999) 95-101
28. Burcoglu-O'Ral A., Erkan D., and Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol 29 (2002) 2006-2011
29. Sprong T., Moller A.S., Bjerre A., et al. Complement activation and complement-dependent inflammation by Neisseria meningitidis are independent of lipopolysaccharide. Infect Immun 72 (2004) 3344-3349
30. Kitchens C.S. Thrombotic storm: when thrombosis begets thrombosis. Am J Med 104 (1998) 381-385
31. Bernard G.R., Ely E.W., Wright T.J., et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29 (2001) 2051-2059
32. Erkan D., and Lockshin M.D. What is antiphospholipid syndrome?. Curr Rheumatol Rep 6 (2004) 451-457
33. Fourrier F. Recombinant human APC in the treatment of severe sepsis. An evidence based review. Crit Care Med 32 (2004) S534-S541
34. Yan S.B., and Dhainaut J.F. Activated protein C versus protein C in severe sepsis. Crit Care Med 29 (2001) S69-S74
35. Opal S.M., and Esmon C.T. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 7 (2003) 23-38
36. De Larranaga G.F., Remondino G.I., Forastiero R.R., et al. Catastrophic antiphospholipid syndrome and Kikuchi-Fujimoto disease: the first case reported. Lupus 14 (2005) 967-969
37. Vincent J.L., Sakr Y., Sprung C.L., et al. Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34 (2006) 344-353
38. Gunnewiek J.M., and Van Der Hoeven J.G. Cardiac troponin elevations among critically ill patients. Curr Opin Crit Care 10 (2004) 342-346
39. Yan S.B., Helterbrand J.D., Hartman D.L., et al. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 120 (2001) 915-922
40. Erkan D., Asherson R.A., Espinosa G., et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 62 (2003) 530-533